Focus: Merck & Co. is a diversified pharmaceutical giant with $60.1B in FY2025 revenue, competing across oncology, vaccines, infectious disease, cardiovascular, and immunology. The company operates at massive scale with 69,000 employees and maintains a fortress balance sheet.
Profile data last refreshed 7h ago · AI intelligence enriched 1w ago
Hot — 1936 jobs added in 30d
Net +355 (1936 new, 1581 removed). Aggressive expansion phase.
2 recent layoff filings (12 mo) — 142 affected
Source: state DOL filings via Big Local News
Merck offers unparalleled R&D scale and oncology depth but faces acute patent cliff pressure and documented layoff activity; best for risk-tolerant candidates seeking oncology or vaccine expertise amid organizational restructuring.
Help build intelligence for Merck & Co.
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Merck & Co.'s SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Merck's revenue anchor but facing cliff expiration in 2.5 years; your diabetes franchise performance directly impacts company stability.
Combination therapy extension of JANUVIA franchise; LOE extends to 2029 but derivative revenue stream.
Extended-release formulation sharing JANUVIA's 2027 cliff; part of $5.191B cumulative diabetes portfolio at risk.
Peak-stage asset with stable exclusivity through 2033; represents newer franchise differentiation.
Generic cardiovascular; post-patent revenue; stable but low-margin business.
HIV integrase inhibitor facing expiration Sept 2029; part of ongoing HIV portfolio pressure.
Specialty infectious disease asset; LOE Jan 2028; narrower indication limits upside.
338 discontinued, 81 duplicate formulations not shown
+27 more products with revenue data
does merck have a weight loss drug - polskieradio.pl
does merck have a weight loss drug polskieradio.pl
Fierce Pharma Asia—AZ’s $2B bet on ivonescimab; Novo buys Hengrui GLP-1; Merck doubles down on KRAS - Fierce Pharma
Fierce Pharma Asia—AZ’s $2B bet on ivonescimab; Novo buys Hengrui GLP-1; Merck doubles down on KRAS Fierce Pharma
Fierce Biotech Layoff Tracker 2026: Foghorn cuts workforce by 40%; BioMarin drops 117 roles - Fierce Biotech
Fierce Biotech Layoff Tracker 2026: Foghorn cuts workforce by 40%; BioMarin drops 117 roles Fierce Biotech
Top 10: Bio-Pharmaceutical Companies - Healthcare Digital
Top 10: Bio-Pharmaceutical Companies Healthcare Digital
does merck have a weight loss drug - polskieradio.pl
does merck have a weight loss drug polskieradio.pl
Mission Bio Showcases Tapestri Across Drug Discovery and Clinical Development at World CDx Summit - CRISPR Medicine News
Mission Bio Showcases Tapestri Across Drug Discovery and Clinical Development at World CDx Summit CRISPR Medicine News
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+33 more products
Source: state DOL filings, aggregated via Big Local News
Layoff velocity is high and ongoing; Rahway HQ and Jersey City are primary restructuring centers; internal mobility risk is elevated for non-R&D roles; job security remains uncertain despite revenue scale.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo